BeiGene's BRUKINSA receives positive NICE recommendation for CLL in UK

BeOne Medicines Ltd.

NICE final draft guidance recommends BRUKINSA for untreated CLL with 17p deletion or TP53 mutation, or when FCR/BR unsuitable, and for relapsed or refractory CLL.
NICE found zanubrutinib cost-effective vs other BTK inhibitors, with lower incremental costs and more QALYs.
Follows NICE's July 2022 recommendation for Waldenstrom's macroglobulinemia and Scottish Medicines Consortium approval on Oct 9, 2023.
BRUKINSA approved in over 65 countries; global development program includes 5,000+ subjects in 29 countries.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.